Follicular thyroid carcinoma (FTC) is not routinely diagnosed by a preoperative fine needle aspiration biopsy (FNAB), and the final diagnosis relies on histopathological criteria visible upon microscopic examination of the excised tumor. Several markers have been proposed as helpful in the identification of follicular thyroid tumors with malignant potential and worse prognosis, of which the specific point mutations C250T and C228T in the Telomerase Reverse Transcriptase (TERT) promoter region seem to be particularly promising. We describe a patient presenting with a large pelvic mass, in which a core needle biopsy was consistent with follicular-patterned thyroid tissue positive for a Q61R NRAS mutation and the C228T TERT promoter mutation. Upon clinical investigation, a 60-mm lesion was detected in the right thyroid lobe. The ensuing FNAB was consistent with a follicular thyroid tumor, Bethesda IV, positive for the same NRAS mutation and both the C228T and C250T TERT promoter mutations. A total thyroidectomy was performed, and a widely invasive FTC was diagnosed. Tumor tissue samples from various parts of the primary lesion were investigated for TERT promoter mutations, displaying C228T in three samples and C250T in one. Interestingly, the C228T mutations showed a coupling to areas with high Ki-67 proliferation indexes. Our data indicate that TERT promoter mutations can exhibit spatial heterogeneity in FTCs, with implications for clinical management as well as providing insights into the molecular biology underlying the tumoral etiology.
Introduction
Two somatic transversions of the Telomerase reverse transcriptase (TERT) gene promoter (chr 5:1,295,228 C>T; termed C228T and chr5:1,295,250 C>T; C250T) are recurrently demonstrated in poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma, but also occur in poorprognosis cases of well-differentiated thyroid carcinomas (papillary thyroid carcinoma (PTC), and follicular thyroid carcinoma (FTC) [1] . TERT encodes the catalytic subunit of telomerase, an enzyme providing immortalization though the maintenance of telomere length, a fundamental hallmark of malignant tumors. The C228T and C250T promoter mutations alter the transcription output of the TERT gene, thereby thought to confer the tumor with a selective growth advantage.
TERT promoter mutational screening has been shown to reveal malignant potential of follicular tumors of uncertain malignant potential (FT-UMPs) and identify patients with PTC and FTC at risk for recurrence [1] [2] [3] [4] [5] [6] [7] , suggesting that the implementation of this analysis is an effective method complementing routine analyses when diagnosing thyroid tumors. Even so, little is known regarding spatial distribution of these mutations within a unique lesion, and if multi-regional sampling affects the sensitivity of the method. We here present evidence of spatial heterogeneity regarding TERT promoter mutations, and emphasize the clinical implications drawn from the results. 
Case Report
The patient is a 56-year old, clinically euthyroid female of Spanish ethnicity without family history of thyroid disease. Twenty years ago, she was investigated for a thyroid nodule (lobe not specified) abroad, with benign cytology according to the patient. In December 2018, she presented with lower back pain and a subsequent CT scan visualized a 60-mm large lesion in conjunction to the left sacroiliac joint adjoined by lytic lesions of the sacrum and the lower vertebrae ( Supplementary  Fig. 1 ). A core-needle biopsy demonstrated follicularpatterned cells with monomorphic nuclei without PTCassociated changes. Immunohistochemistry demonstrated positivity for TTF1, PAX8, and thyroglobulin, raising the suspicion of the lesion being metastatic with an assumed primary location in the thyroid. Molecular genetic analyses using the targeted exome-sequencing platform Oncomine Solid Tumor Panel (Ion Torrent S5, Thermo Scientific, MA, USA) and DNA extracted from formalin-fixated paraffin-embedded core-needle biopsy material revealed a Q61R NRAS mutation, and separate Sanger sequencing of the TERT promoter region revealed the C228T mutation, strengthening the suspicion of metastatic FTC. Clinical evaluation including a neck MRI and ultrasonography revealed an enlarged right thyroid lobe (5 × 6 × 6.5 cm) with a heterogeneous and tumorous appearance. A fine needle aspiration biopsy (FNAB) showed a follicular thyroid tumor, Bethesda IV, positive for the same NRAS mutation, but surprisingly displaying both C228T and C250T TERT promoter mutations (Fig. 1) . Although the dissimilar TERT promoter mutation profiles could imply that the follicular thyroid tumor and the pelvic lesion were unrelated, the common denominator of NRAS mutations argued in favor of an FTC with a synchronous metastatic deposit. The patient underwent a total thyroidectomy upfront, and the pathology examination revealed a 60-mm large, heterogenous tumor with multiple areas displaying capsular and vascular invasion compatible with a widely invasive FTC (pT3aNXM1, R0). Four different areas of the primary tumor were submitted for TERT promoter sequencing, revealing three areas with the C228T mutation and one area with the C250T mutation (Fig. 1) . The Ki-67 proliferation indexes were 8%, 8.1%, and 8.5% for the C228T areas and 2.9% for the C250T area (Fig. 1) . Fig. 1 Gross, microscopic, and molecular findings of the follicular thyroid carcinoma specimen. The central images depict gross findings of a follicular tumor with heterogeneous appearance, with multinodular, solid, yellow-brownish cut surface with remnants of a capsular structure. Measurement bar in centimeters. Each black square (1-4) depicts area chosen for Sanger sequencing of the TERT promoter, and each of these regions are represented with routine histology (hematoxylin-eosin staining), a Ki-67 proliferation index as well as a chromatogram depicting the TERT promoter region including positions C228 and C250. Note how samples 1-3 have a dense, micro-follicular pattern, elevated Ki-67 scores and display the C228T mutation, while sample 4 is less cell-rich, has a lower Ki-67 index and exhibits the C250T mutation. The top central chromatogram is a representation of the preoperative cytological examination, displaying the C228T and C250T TERT promoter mutations Discussion TERT promoter mutational screening is rapidly gaining ground as a confident rule-in marker of malignant properties in follicular thyroid tumors, as the occurrence of a mutation is a strong predictor of future recurrences and worse patient outcome. Moreover, as TERT immunohistochemistry displays poor correlation to overall mRNA expression in FTCs, mutational screening remains the most clinically consistent method to detect cases with aberrancies in the TERT axis [8] . In all, TERT promoter mutational screening should be considered as a reliable complimentary diagnostic marker in equivocal FT-UMP cases as well as a prognostication tool for FTCs in general [2, 4] . Until now, TERT promoter mutations have not been considered as subclonal events in thyroid cancer, and no clear guidelines as to how extensive the mutational testing should be in terms of numbers of tissue blocks submitted for analysis exist. As the TERT promoter mutations were spatially heterogeneous in this FTC, this indicates expansions of specific C228T and C250T clones that could merit further attention regarding the underlying molecular biological mechanisms driving metastatic spread. Indeed, similar observations have been made in meningioma [9] . In our case, the initial finding of dissimilar mutations generated an uncertainty regarding the relation between the thyroid tumor and the pelvic lesion, as the fact that FTCs can harbor both the C228T and C250T mutations was not obvious at the time of diagnosis. The notion that FTCs might display a spatial heterogeneity regarding these mutations is therefore of clinical importance.
In the primary tumor, we observed an association between high proliferation and the C228T mutation. Given the presence of this mutation also in the metastatic lesion, it is likely that the metastasis originated from one of these areas with high Ki-67 proliferation index. As local differences in TERT promoter mutational status could affect the interpretation of the analysis, a multi-regional sampling methodology or sampling of areas with high Ki-67 indexes could in theory increase the accuracy of the method.
We conclude that TERT promoter mutations can exhibit spatial heterogeneity in FTCs, providing insights to molecular underpinnings as well as clinical management of the disease. 
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